{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"178"}]}],"title":"% Base Line Patient 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"105"}]}],"title":"% Base Line Patient 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"105"}]}],"title":"% Base Line Patient 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"99"}]}],"title":"% Base Line Patient 6"},{"categories":[{"measurements":[{"groupId":"OG000","value":"95"}]}],"title":"% Base Line Patient 7"},{"categories":[{"measurements":[{"groupId":"OG000","value":"119"}]}],"title":"% Base Line Patient 8"},{"categories":[{"measurements":[{"groupId":"OG000","value":"128"}]}],"title":"% Base Line Patient 10"},{"categories":[{"measurements":[{"groupId":"OG000","value":"84"}]}],"title":"% Base Line Patient 11"},{"categories":[{"measurements":[{"groupId":"OG000","value":"125"}]}],"title":"% Base Line Patient 13"},{"categories":[{"measurements":[{"groupId":"OG000","value":"120"}]}],"title":"% Base Line Patient 14"},{"categories":[{"measurements":[{"groupId":"OG000","value":"96"}]}],"title":"% Base Line Patient 15"},{"categories":[{"measurements":[{"groupId":"OG000","value":"98"}]}],"title":"% Base Line Patient 16"},{"categories":[{"measurements":[{"groupId":"OG000","value":"431"}]}],"title":"% Base Line Patient 17"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"The primary endpoint is the change in bone Alkaline Phosphatase at baseline and 6 weeks.","groups":[{"description":"All participants enrolled.\n\nBortezomib: Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 8, 15, and 22 of each 42 day cycle.\n\nPatients will undergo nine 42-day cycles. At the end of this (day 378), patients will be assessed for bone remodeling changes. Evaluation for toxicities will be evaluated at the beginning of each cycle.","id":"OG000","title":"Arm 1 Bortezomib"}],"paramType":"NUMBER","populationDescription":"Only 13 patents had bone alkaline phosphatase measured at the appropriate time points out of the 17 that completed the study","reportingStatus":"POSTED","timeFrame":"Baseline and 6 weeks","title":"Bone Anabolic Effect of Bortezomib in Patients With Smoldering Myeloma.","type":"PRIMARY","unitOfMeasure":"Percentage of Baseline Value"}